COMPANY PROFILE / #2719
Cyted Health
Cambridge, United KingdomVenture Capital-Backed
OVERVIEW
Developer of non-endoscopic diagnostic technology designed for the early detection of esophageal diseases and cancer. The company's minimally invasive capsule sponge device, combined with advanced molecular diagnostics, enables safe and accessible esophageal cell collection in community settings, helping clinicians identify precursors like Barrett's Esophagus and move patients toward earlier treatment.
已融资67.87
最新估值51.46
员工数74
成立年份2018
公司概况
- Companies
- Cyted Health
- Description
- Developer of non-endoscopic diagnostic technology designed for the early detection of esophageal diseases and cancer. The company's minimally invasive capsule sponge device, combined with advanced molecular diagnostics, enables safe and accessible esophageal cell collection in community settings, helping clinicians identify precursors like Barrett's Esophagus and move patients toward earlier treatment.
- Website
- www.cytedhealth.com
- HQ Location
- Cambridge, United Kingdom
- Year Founded
- 2018
- Keywords
- cancer detection, cancer diagnoses, clinical diagnostics, diagnostic technique, early diagnostics, molecular diagnostics
- Competitors
- bioZhena, TytoCare, Gene By Gene, Ava (Monitoring Equipment), Scanwell Health, WellnessFX
- Ownership Status
- Privately Held (backing)
- Company Financing Status
- Venture Capital-Backed
融资与估值
- Total Raised
- 67.87
- First Financing Date
- 23-Jul-2018
- First Financing Size
- —
- First Financing Valuation
- —
- Last Financing Date
- 29-Aug-2025
- Last Financing Deal Type
- Later Stage VC
- Last Financing Size
- 43.76
- Last Financing Valuation
- 51.46
- Last Financing Status
- Completed
- Last Known Valuation
- 51.46
- Last Known Valuation Date
- 29-Aug-2025
- Last Known Valuation Deal Type
- Later Stage VC
- Valuation Estimate
- 82.20
- Valuation Estimate Growth Rate
- 59.73%
- Active Investors
- Advent Life Sciences, BGF (Financial Services), British Business Bank, Cancer Research Horizons, EQT Life Sciences, Innovate UK, MedTech Innovator, Morningside Group, SBRI Healthcare, Small Business Research Initiative, University of Cambridge
- # Active Investors
- 11
- Acquirers
- —
团队与联系人
- Employees
- 74
- Employee Growth %
- 17.46%
- Employee History
- 2026: 74, 2025: 63, 2024: 76, 2023: 64, 2022: 61, 2021: 25, 2020: 25, 2019: 3
- Primary Contact
- Marcel Gehrung
- Primary Contact Title
- Co-Founder, Chief Executive Officer & Board Member
- Primary Contact Email
- marcel.gehrung@cyted.ai
- Primary Contact Phone
- +44 (0)14 8045 3437
增长与经营
- Revenue
- 5.32
- Revenue Growth %
- 39.77%
- Growth Rate
- 0.62%
- Growth Rate % Change
- —
- Growth Rate Percentile
- 95
- Size Multiple
- 7.95x
- Size Multiple % Change
- 0.00%
- Size Multiple Change
- 0.00x
- Size Multiple Percentile
- 90
- Majestic Referring Domains
- 173
- SimilarWeb Unique Visitors
- 472
- SimilarWeb Unique Visitors Change
- 50
- SimilarWeb Growth Rate
- —
- SimilarWeb Growth Rate Percentile
- —
- Success Probability Over Time – 1 Year
- 4%
- Success Probability Over Time – 3 Year
- 16%
- Success Probability Over Time – 5 Year
- 26%
记录来源：public.companies · 原始序号 #2719 · 所有字段均按数据库原值展示。